BLASUBCUTANEOUSINJECTABLE
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
OMVOH (mirikizumab-mrkz) by Eli Lilly and Company is interleukin-23 antagonists [moa]. Approved for interleukin-23 antagonist [epc]. First approved in 2023.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMVOH (mirikizumab-mrkz) is a monoclonal antibody that antagonizes interleukin-23, a key cytokine in inflammatory immune responses. It is approved for ulcerative colitis, Crohn's disease, psoriasis, and pouchitis, delivered via subcutaneous injection. The drug targets patients with moderate-to-severe inflammatory bowel disease and psoriasis who require biologic intervention.
Growth
Early-stage growth product with moderate competitive pressure (30/100); commercial team focus on market penetration and indication expansion during critical establishment phase.
Mechanism of Action
Interleukin-23 Antagonists
Pharmacologic Class:
Interleukin-23 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis
Started Jul 2025
150 enrolled
Crohn Disease (CD)Crohns DiseaseUlcerative Colitis (UC)
A Study of Mirikizumab (LY3074828) Injection in Healthy Participants
Started Apr 2017
67 enrolled
Healthy
A Safety Study of Mirikizumab (LY3074828)
Started Oct 2013
45 enrolled
Psoriasis
Career Relevance
OMVOH roles center on market establishment and competitive differentiation in a crowded immunosuppression space; roles emphasize competitor intelligence, physician education, and payer strategy. Growth-stage product offers career advancement potential but requires agility in a landscape where JAK inhibitors and established IL-23 competitors already dominate.
Worked on OMVOH at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.